Table 6

Mean cognitive function by follow-up time point and according to donepezil added to stimulation therapy versus placebo added to standard care
Groups Time points
Baseline n = 87 4 months n = 76 8 months n = 74 12 months* n = 69 p-value1 p-value2
MMSE ± SD**
Donepezil + stimulation therapy 22.9 ± 4.5 22.9 ± 4.5 22.9 ± 4.9 22.5 ± 5.5 0.443 0.449
Placebo + standard care 23.3 ± 4.9 23.8 ± 4.2 23.6 ± 4.6 24.1 ± 4.7
Clock Drawing Test ± SD**
Donepezil + stimulation therapy 2.9 ± 1.1 2.9 ± 1.1 2.8 ± 1.2 3.1 ± 1.0 0.064 0.035
Placebo + standard care 2.9 ± 1.2 3.2 ± 1.0 3.3 ± 1.0 3.3 ± 1.1
ADAS-cog ± SD**
Donepezil + stimulation therapy 19.3 ± 8.7 19.2 ± 8.2 17.2 ± 9.5 16.1 ± 8.7 0.554 0.458
Placebo + standard care 17.2 ± 8.0 16.3 ± 7.1 16.3 ± 8.5 15.1 ± 7.9

* n varies due to missing values ** Standard deviation. p-value1 = Equal time trends between groups. p-value2 = Equal time trend between groups adjusted for baseline cognitive function.

Andersen et al.

Andersen et al. BMC Neurology 2012 12:59   doi:10.1186/1471-2377-12-59

Open Data